Navigation Links
Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis for BEACON Pivotal Phase 3 Clinical Study in Patients with Metastatic Breast Cancer
Date:1/14/2014

and taxanes (AT) are the most active and widely used chemotherapeutic agents for breast cancer, but the increased use of these agents at an early stage of disease often renders tumors resistant to these drugs by the time the disease recurs, thereby reducing the number of treatment options for metastatic disease. Drugs used to treat patients who progress following AT treatment can have response rates as high as 20-30%; however, resistance develops rapidly and new agents with different mechanisms of action, such as topoisomerase I inhibitors, are needed to allow novel ways to overcome the problem of drug resistance. (4) There are currently no FDA-approved topoisomerase I inhibitors to treat breast cancer.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other therapeutic areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for naloxegol (NKTR-118), an investigational drug candidate, which has been filed for regulatory approvals in the U.S., Europe and Canada as a once- daily, oral tablet for the treatment of opioid-induced constipation.  This agreement also includes NKTR-119, an earlier stage development program that is a co-formulation of naloxegol and an opioid.  NKTR-181, a novel mu-opioid analgesic candidate for chronic pain conditions, has completed Phase 2 development in osteoarthritis patients with chronic knee pain.  NKTR-192, a novel mu-opioid analgesic in development to treat acute pain is in Phase 1 clinical development.  In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneum
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
2. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
3. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
4. Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma
5. CAS REGISTRY(SM) surpasses 75 million small molecules
6. WuXi Manufacturing Facility Passes FDA Inspection
7. Tecfideras Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
8. Emotivs Brainwear Technology To Track Cognitive Health Surpasses $1M Kickstarter Stretch Goal
9. The Leukemia & Lymphoma Society Co-Pay Assistance Fund Surpasses $200 Million
10. French Man with SynCardia Total Artificial Heart Surpasses Two Years of Support
11. NABPs .PHARMACY Proposal Passes Initial ICANN Evaluation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mich. , Sept. 19, 2014  Diplomat, the ... of David Dreyer to the Board of ... independent director and will also serve as chair of ... almost 30 years of accounting, financial, compliance and operating ... Mr. Dreyer has served as chief financial officer, chief ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
(Date:9/19/2014)... , Sept. 19, 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® in the ... that BioSpecifics, President, Tom Wegman , will present a ... in the Biotech Industry Conference. The presentation ... p.m. EDT at the Millennium Broadway Hotel in ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... Fla., May 8, 2012 Grappling with economic uncertainty, ... industry is on the cusp of major changes, said ... opening session of the 2012 GHX Healthcare Supply Chain ... GPOs and distributors gathered this week in Orlando for ...
... DIEGO, May 8, 2012 Aethlon Medical, Inc. ... filtration devices to address infectious disease, cancer and other ... C virus (HCV) is currently undetectable in all infected ... in combination with peginterferon+ribavirin (PR) drug therapy and monitored ...
Cached Medicine Technology:GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 2GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 3Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 2Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 3Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 4Aethlon Medical Reports Undetectable Hepatitis C Virus (HCV) in Genotype 1, Genotype 3, and Genotype 5 Patients Treated with Hemopurifier® Therapy 5
(Date:9/20/2014)... 20, 2014 Lifeinsurancequoteterm.net has released ... no medical exam life insurance plan provides for vulnerable ... family members should be a top priority for every ... insurance without taking medical examinations and visiting a doctor. ... medical examinations will provide coverage up to $300,000, but ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Ticket Down ... concert tickets for her 2015 “Honeymoon Tour.” This ... ARIANA-2015 for added savings. , In early 2015, fans will ... in the world across North America. Twenty-one-year-old Ariana Grande will ... which will take her to 25 cities across the United ...
(Date:9/20/2014)... 20, 2014 Recently, Best Cheap ... has launched its new website. The new site ... popular hosting products for customers. Here, people can ... a purchasing decision. Also, it has recommended some ... , One of the great web hosting suppliers, ...
(Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
(Date:9/20/2014)... RBSEO Services, which has occupied a ... announced it provides an affordable website SEO (Search Engine ... announcement would benefit those new and old businesses struggling ... afford to pay a big amount for their website ... websites in top search results for their business keywords ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance Provides Financial Protection for Families 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 2Health News:Ariana Grande Tickets in New York, Philadelphia, Orlando, Fairfax, Worcester, Toronto, Uncasville, Detroit, Miami, Pittsburgh, Cleveland, and Atlanta On Sale Today 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:RBSEO Services Announces Affordable Website SEO Service at Only $175 2
... what do you get for the nut,that has everything, including ... Doctor Chuck talking therapy doll?, You can at once ... who needs it, their own personal and portable psychotherapist. The,Ask ... line, which could,earn you the undying gratitude of the rest ...
... Higher-risk Myelodysplastic Syndromes (MDS), Thalidomide in Multiple ... ... 6 Pharmion Corporation,(Nasdaq: PHRM ) reported today that data ... products will,be presented at the American Society of Hematology,s (ASH) 49th ...
... Arete Therapeutics Inc., a,privately-held biopharmaceutical company developing first-in-class ... and,metabolic diseases, today announced the appointment of Donald ... are very pleased to welcome Don to our ... will be of great benefit to the Company,as ...
... Company Projects Seven Products to Reach Sales of $1 Billion or More in ... 2008, - ... ... Gains plus Aggressive Deal-Making Result in Unprecedented ...
... StemCor Systems, Inc., a,medical device company ... that it has acquired U.S. Patent 6,849,051,"Devices ... and associated,know-how from USPure Sciences, LLC. The ... samples from bone cavities. The concept and,technologies ...
... 5 EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: ... will present a company overview at the New ... & Specialty Pharma,Conference on December 12, 2007 at ... at the NYSSA,s headquarters at 1177 Avenue of ...
Cached Medicine News:Health News:The Cure for Holiday Stress 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 2Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 3Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 4Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 5Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 6Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 7Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 8Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 9Health News:Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting 10Health News:Arete Therapeutics Appoints Donald Santel to Board of Directors 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 2Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 3Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 4Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 5Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 6Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 7Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 8Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 9Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 10Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 11Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 12Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 13Health News:Lilly Showcases Pipeline Opportunities to Wall Street, Sets 2008 Financial Guidance and Outlines Transformation Strategy 14Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 2Health News:StemCor Systems Announces Acquisition of Intellectual Property to Enhance Bone Marrow Aspiration Platform 3Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 2Health News:EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: